Oxaliplatin-induced hepatocellular injury and ototoxicity: A review of the literature and report of unusual side effects of a commonly used chemotherapeutic agent

Journal of Oncology Pharmacy Practice

Volumn 18, Issue 3, 2012, Pages 355-359

  Vietor, Nicole O ^a   George, Benjamin J ^a  

^a BROOKE ARMY MEDICAL CENTER   (United States)

Author keywords

colorectal cancer; hepatocellular; liver associated enzymes; ototoxicity; Oxaliplatin

Indexed keywords

FLUOROURACIL; FOLINIC ACID; OXALIPLATIN;

ADJUVANT CHEMOTHERAPY; ADULT; CANCER COMBINATION CHEMOTHERAPY; CASE REPORT; CAUCASIAN; DRUG INDUCED DISEASE; EMERGENCY WARD; FEMALE; GASTROINTESTINAL CARCINOMA; HEMATOCHEZIA; HUMAN; LIVER CELL DAMAGE; MEDICAL HISTORY; OTOTOXICITY; PRIORITY JOURNAL; REVIEW; SIGMOID CARCINOMA; SIGMOIDECTOMY;

ADENOCARCINOMA; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG-INDUCED LIVER INJURY; FEMALE; FLUOROURACIL; HUMANS; LEUCOVORIN; MIDDLE AGED; NEOPLASM STAGING; ORGANOPLATINUM COMPOUNDS; SIGMOID NEOPLASMS; TINNITUS; VERTIGO;

EID: 84865637635     PISSN: 10781552     EISSN: 1477092X     Source Type: Journal    
DOI: 10.1177/1078155212437901     Document Type: Review

References (23)

1. De Gramont A, Figer A, Seymour M, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol. 2000 ; 18: 2938-2947
2. André T, Boni C, Mounedji-Boudiaf L, et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med. 2004 ; 350: 2343-2351
3. Cunningham D, Starling N, Rao S, et al. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med. 2008 ; 358: 36-46
4. Saltz L, Clarke L, Díaz-Rubio E, et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol. 2008 ; 26: 2013-2019
5. Becouarn Y, Ychou M, Ducreux M, et al. Phase II trial of oxaliplatin as first-line chemotherapy in metastatic colorectal cancer patients. Digestive Group of French Federation of Cancer Centers. J Clin Oncol. 1998 ; 16: 2739-2744
6. Giacchetti S, Perpoint B, Zidani R, et al. Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. J Clin Oncol. 2000 ; 18: 136-147
7. Extra J, Espie M, Calvo F, et al. Phase I study of oxaliplatin in patients with advanced cancer. Cancer Chemother Pharmacol. 1990 ; 25: 299-303
8. Diaz-Rubio E, Sastre J, Zaniboni A, et al. Oxaliplatin as single agent in previously untreated colorectal carcinoma patients: a phase II multicentric study. Ann Oncol. 1998 ; 9: 105-108
9. Cassidy J, Misset JL. Oxaliplatin-related side effects: characteristics and management. Semin Oncol. 2002 ; 29: 11-20
10. O'Dea D, Handy CM, Wexler A. Ocular changes with oxaliplatin. Clin J Oncol Nurs. 2006 ; 2: 227-229
11. Berretta M, Taibi R, Bearz A, et al. Dysphonia as an unusual toxic event of oxaliplatin-based chemotherapy. J Chemother. 2004 ; 6: 595-598
12. Butt W, Saadati H, Saif MW. Oxaliplatin-induced pancreatitis: a case series. Anticancer Res. 2010 ; 12: 5113-5115
13. Ulusakarya A, Misra S, Haydar M, et al. Acute renal failure related to oxaliplatin-induced intravascular hemolysis. Med Oncol. 2010 ; 4: 1425-1426
14. Vauthey J, Pawlik T, Ribero D, et al. Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases. J Clin Oncol. 2006 ; 24: 2065-2072
15. Rubbia-Brandt L, Audard V, Sartoretti P, et al. Severe hepatic sinusoidal obstruction associated with oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer. Ann Oncol. 2004 ; 15: 460-466
16. Ryan P, Nanji S, Pollett A, et al. Chemotherapy-induced liver injury in metastatic colorectal cancer: Semiquantitative histologic analysis of 334 resected liver specimens shows that vascular injury but not steatohepatitis is associated with preoperative chemotherapy. Am J Surg Pathol. 2010 ; 34: 784-791
17. Arotçarena R, Calès V, Berthelémy P, et al. Severe sinusoidal lesions: a serious and overlooked complication of oxaliplatin-containing chemotherapy?. Gastroenterol Clin Biol. 2006 ; 11: 1313-1316
18. Moroso M, Blair R. A review of cis-platinum ototoxicity. J Otolaryngol. 1983 ; 12: 356-359
19. Seligman H, Podoshin L, Ben-David J, et al. Drug-induced tinnitus and other hearing disorders. Drug Saf. 1996 ; 14: 198-212
20. Reddel R, Kefford R, Grant JM, et al. Ototoxicity in patients receiving cisplatin: importance of dose and method of drug administration. Cancer Treat Rep. 1982 ; 66(1): 19-23
21. Rabik CA, Dolan ME. Molecular mechanisms of resistance and toxicity associated with platinating agents. Cancer Treat Rev. 2007 ; 33: 9-23
22. Montaguti M, Brandolini C, Ferri GG, et al. Cisplatin and carboplatin-induced ototoxicity in children: clinical aspects and perspectives for prevention. Acta Otorhinolaryngol Ital. 2002 ; 22: 14-18
23. Naranjo C, Dusto V, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981 ; 30: 239-245